Par Pharmaceutical - Generic Company Intelligence Report

Table of Contents

Executive Summary

Introduction

• Kali Laboratories

Products

• Teva/IVAX Drugs Divested to Par Pharmaceutical Companies
• Par Pharmaceutical ANDA Approvals, 2002-06
• Kali Laboratories ANDA Approvals, 2004-06
• Recent Product Approvals
  • Ondansetron
  • Pravastatin
  • Companies gain meloxicam approvals
  • Orchid gains cephalexin ANDA approval
  • Amlodipine besylate tablets (tentative)
  • Tranylcypromine sulphate tablets
  • Miralax generic

Financial results

• Par Pharmaceutical Financial Results 2001-05 (US$000s)
• Generic/Branded Revenues & Operating Income, 2003-05 (US$000s)
• Par Sales of Selected Generic Products, 2003-05 (US$000s)

Major Developments

• Mergers, acquisitions and agreements
  • AstraZeneca/Par enter agreement for generic version of Toprol-XL
  • Spectrum Pharmaceuticals
    • Sumatriptan injection
  • Par divests FineTech
  • Bradley and Par enter licensing agreement for Adoxa
  • MN Pharmaceuticals
  • Orchid Chemicals & Pharmaceuticals
• Litigation
  • Reliant files patent infringement lawsuit against Par over Rythmol
  • Unimed, Watson, Paddock and Par enter settlement agreements regarding AndroGel litigation

Contact Details